nivolumab,ipilimumab,regorafenib
bms,bayer
['nivolumab', 'ipilimumab', 'nivo', 'rectal', 'regorafenib', 'colorectal']
regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial, from , free to read online during #asco23 
JAMA #Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology.